Bone Marrow & Stem Cell Transplant

Post-transplant gilteritinib maintenance may boost survival and reduce relapse in relapsed FLT3-mutated AML, though larger trials are still needed.

Phase 3 results show that fecal microbiotherapy achieved a 62% GI response rate and a 54% 1-year survival in patients who had failed both corticosteroids and ruxolitinib.

Fifty patients are enrolled to receive EBX-102-02 or placebo to address gut microbiome disruption associated with allogeneic hematopoietic cell transplant.

A validated analysis of nearly 22,000 patients receiving allogeneic hematopoietic cell transplant led to development of a risk calculator for acute graft-vs-host disease.

A trial found that off-the-shelf TRX103 Tr1 cells were safe to use after a mismatched donor stem cell transplant, showing engraftment, dose-dependent expansion, and persistence.

A phase 2 trial of acalabrutinib led to favorable response rates and tolerability in steroid-refractory chronic GVHD.

A trial of ustekinumab as graft-vs-host disease (GVHD) prophylaxis after hematopoietic cell transplant did not meet its primary end point but showed more favorable outcomes in patients who had myeloablative conditioning.

Higher doses of anti–T-lymphocyte globulin significantly reduce chronic graft-vs-host disease in matched sibling stem cell transplants, enhancing patient outcomes.

During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease.

Orca-T immunotherapy shows promising results in improving survival and reducing complications in patients with hematologic malignancies compared to traditional treatments.

New research reveals mismatched unrelated donors significantly improve transplant outcomes, expanding options for diverse patients in need of life-saving procedures.

MaaT013 shows promising efficacy and safety in treating refractory GI-aGVHD, offering hope for improved survival in patients.

New findings reveal the feasibility and safety of transitioning axatilimab dosing for chronic graft-vs-host disease, showing promising response rates.

During a live event, Hannah Choe, MD, discussed options for steroid-resistant cGVHD based on organ involvement, efficacy, and safety profiles.

Research reveals matched unrelated donor transplants significantly enhance survival rates in leukemia patients compared with haploidentical transplants, despite donor availability.

New response criteria for acute GVHD enhance prediction of nonrelapse mortality, potentially transforming clinical trial designs and treatment evaluations.

During a live event, Hannah Choe, MD, and event participants discuss steroid-dependent chronic GVHD, favoring adding therapy over increasing steroids.

New research highlights narsoplimab's potential to significantly reduce mortality in high-risk patients with thrombotic microangiopathy after stem cell transplants.

New research reveals that sustained MRD negativity after ASCT allows safe discontinuation of lenalidomide maintenance in multiple myeloma patients.

A recent study reveals that alternative donors for hematopoietic cell transplants yield similar success rates as fully matched donors, enhancing patient outcomes.

A new study reveals that optimized donor search algorithms significantly enhance transplant outcomes for patients, even with alternative donor sources.

A new study explores strategies to enhance survival rates for patients facing challenges in finding bone marrow donors, advocating for quicker alternative options.

A new trial reveals PTCy and abatacept significantly reduce chronic GVHD in stem cell transplant patients, offering promising outcomes over standard care.

A study reveals significant survival disparities in plasma cell leukemia, highlighting the benefits of stem cell transplantation for patient outcomes.